论文部分内容阅读
目的:通过体外细胞实验,来确定对RGD-TRAIL的敏感肿瘤细胞株,为体内试验提供参考。方法:利用靶向抗肿瘤蛋白RGD-TRAIL处理30株人肿瘤细胞系72 h后,通过CTG方法测定药物在各个肿瘤细胞系中的细胞增殖50%抑制浓度(IC50),来确定对RGD-TRAIL的敏感肿瘤细胞株。结果:在所有测试的肿瘤细胞系中,对RGD-TRAIL最为敏感的是COLO 205,A-673和NCI-H358,它们的IC50皆小于0.05μg·m L-1;其次MDA-MB-231和Calu-3对RGD-TRAIL也较敏感,IC50值分别为0.3和1.9μg·m L-1;其余细胞系对RGD-TRAIL的IC50值均大于40μg·m L-1。结论:对RGD-TRAIL敏感的肿瘤细胞株为COLO 205(结肠癌)、A-673(骨癌)和NCI-H358(非小细胞肺癌)。
OBJECTIVE: To determine RGD-TRAIL-sensitive tumor cell lines by in vitro cell-based assays and to provide a reference for in vivo experiments. METHODS: After treating 72 human cancer cell lines with the targeted anti-tumor RGD-TRAIL for 72 h, the cell proliferation 50% inhibitory concentration (IC50) of the drug in each tumor cell line was determined by the CTG method to determine the effect of RGD-TRAIL Of sensitive tumor cell lines. RESULTS: Of all the tumor cell lines tested, the most sensitive to RGD-TRAIL were COLO 205, A-673 and NCI-H358, all with IC50 of less than 0.05 μg · mL -1; followed by MDA-MB-231 and Calu-3 was also sensitive to RGD-TRAIL with IC50 values of 0.3 and 1.9 μg · mL -1, respectively. IC50 values of RGD-TRAIL in other cell lines were all higher than 40 μg · m L -1. CONCLUSIONS: RGD-TRAIL-sensitive tumor cell lines are COLO 205 (colon cancer), A-673 (bone cancer) and NCI-H358 (non-small cell lung cancer).